In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was appointed to lead the organization following the retirement of Dr. Steven Pearson. Sarah outlines her vision for ICER and the priorities for strengthening the framework and collaboration to achieve their mission of evaluating the comparative effectiveness of new medicines. Sarah also discusses ICER’s efforts to expand patient engagement and the evaluation of payers to ensure fair access to medicine.

• Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER)

• Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER)

• Barriers to Fair Access Report

• Gross-to-Net Bubble

• Pharmacy Benefit Managers (PBMs)

• Humira biosimilars

• Institute for Clinical and Economic Review (ICER)

• 340B Drug Pricing Program

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

In this episode, we sit down with Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center to discuss the critical healthcare and policy trends shaping 2025. From shifts in federal leadership to the evolving impact of the Inflation Reduction Act, our guest provides expert insights on what to expect in drug pricing, health insurance, and patient access in the coming year. We explore how the public and private sectors are addressing affordability challenges and highlight innovative approaches to improve access to essential medications. With a focus on the future, this conversation offers a thoughtful outlook on the policies and market dynamics set to redefine healthcare in 2025.

Stacie Dusetzina, Ph.D., Vanderbilt University

Vanderbilt University Medical Center

A primer on copay accumulators, copay maximizers, and alternative funding programs

IRA

Medicare Part D

Pharmacy Benefit Managers (PBMs)

Medicaid

CMMI’s Medicaid group negotiation

COVID-19

Statins

PCSK9 inhibitors

Imatinib

340B Drug Pricing Program

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.

Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
Eric Faulkner, President, Passage Health Associates
ADVI Health
Alliance for Regenerative Medicine
ARPA-H
Bespoke Gene Therapy Consortium
Blue Bird Bio
Blue Cross Blue Shield
Medicare DRG Rates
NICE (National Institute for Health and Care Excellence)
Novartis
Passage Health Associates
REMS Program
Single Case Agreements
Spark Therapeutics

Medical terminology referenced in this episode:

• Alzheimer's
• Aspheresis
• CAR T therapy
• Hemophilia
• Hepatitus C
• Luxturna
• Metachromatic leukodystrophy
• Myeloablative Conditioning
• Sickle Cell Disease
• SMA treatment
• Spinraza
• Vaso Occlusive Crises
• Zolgensma